Amedisys, Inc. (NASDAQ:AMED) Stock Holdings Increased by Bank of Nova Scotia

Bank of Nova Scotia lifted its holdings in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 177.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 111,000 shares of the health services provider's stock after buying an additional 71,000 shares during the quarter. Bank of Nova Scotia owned approximately 0.34% of Amedisys worth $10,078,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of AMED. Blue Trust Inc. raised its stake in shares of Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after acquiring an additional 124 shares in the last quarter. HBW Advisory Services LLC acquired a new position in Amedisys in the fourth quarter worth about $38,000. Versant Capital Management Inc boosted its stake in Amedisys by 68.5% in the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock valued at $41,000 after buying an additional 183 shares in the last quarter. Vestcor Inc bought a new position in Amedisys during the 4th quarter valued at about $73,000. Finally, Venturi Wealth Management LLC lifted its position in Amedisys by 397.4% during the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock worth $89,000 after buying an additional 779 shares in the last quarter. Institutional investors own 94.36% of the company's stock.

Amedisys Trading Down 0.1 %

Shares of Amedisys stock traded down $0.08 during midday trading on Wednesday, reaching $91.50. 24,759 shares of the company's stock traded hands, compared to its average volume of 313,814. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95. The stock has a 50 day moving average of $92.17 and a 200-day moving average of $91.98. The company has a market cap of $3.00 billion, a PE ratio of 36.31, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89.

Remove Ads

Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing analysts' consensus estimates of $1.05 by ($0.09). The firm had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. As a group, equities analysts expect that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on AMED. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 target price on shares of Amedisys in a research note on Wednesday. Stephens reiterated an "equal weight" rating and set a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.